Gut Check: Gastric and Esophageal Cancer Treatment Evolves

Oncology pharmacists managing patients with gastric and esophageal cancers now have a novel therapeutic agent to work with.Zolbetuximab (Vyloy, Astellas), the first-in-class CLDN18.2-targeting monoclonal antibody approved last year for first-line HER2-negative gastric and esophagogastric junction (EGJ) adenocarcinoma, can extend overall survival (OS) beyond the 18-month mark for eligible patients, explained Jeremy Pappacena, PharmD, BCOP, a clinical pharmacy specialist in medical oncology at All